This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
by Ekta Bagri
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
by Kinjel Shah
PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
by Sundeep Ganoria
CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
by Zacks Equity Research
VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Bristol Myers Squibb (BMY) concluded the recent trading session at $48.66, signifying a -2.19% move from its prior day's close.
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
by Ekta Bagri
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
by Kinjel Shah
PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.
BMY Reports Positive Data on Sotyktu From Arthritis Study
by Zacks Equity Research
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
The latest trading day saw Bristol Myers Squibb (BMY) settling at $49, representing a +1.22% change from its previous close.
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
by Ekta Bagri
SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
by Ekta Bagri
BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
by Zacks Equity Research
MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?
by Zacks Equity Research
EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations.
Bristol Myers Collaborates With BNTX for Oncology Candidate
by Zacks Equity Research
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $48.79, moving +1.06% from the previous trading session.
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
by Zacks Equity Research
Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on investor sentiment.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.